Clinical utility of monitoring serial CA 27.29 in patients with different stage of breast cancer

Vikas Ghai; Kamal Sharma; Kamal K.S. Abbi; Harold A. Harvey

doi:10.2174/1876817201103010029

Clinical utility of monitoring serial CA 27.29 in patients with different stage of breast cancer

Vikas Ghai, Kamal Sharma, Kamal K.S. Abbi, Harold A. Harvey

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Breast cancer is by far the most frequent cancer in women, worldwide and ranks third overall when both sexes are considered together. For many malignancies, serum tumor markers play an important role in patient management. MUC-1 glycoprotein based serum markers (CA15-3 and CA 27.29) are assays approved by the US Food and Drug Administration for monitoring patients with advanced breast cancer. Potential applications include early detection of recurrent disease and monitoring treatment efficacy in patients with advanced disease. While retrospective data regarding the role of CA27.29 correlates well with progression and treatment of metastatic breast cancer, a multicenter prospective study to further assess the role of CA 27.29 for monitoring of locally advanced disease is warranted.

Original language	English (US)
Pages (from-to)	29-30
Number of pages	2
Journal	Open Breast Cancer Journal
Volume	3
DOIs	https://doi.org/10.2174/1876817201103010029
State	Published - 2011

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2174/1876817201103010029

Cite this

@article{fc79a767d05b4e898cc92d5ffdff5869,

title = "Clinical utility of monitoring serial CA 27.29 in patients with different stage of breast cancer",

abstract = "Breast cancer is by far the most frequent cancer in women, worldwide and ranks third overall when both sexes are considered together. For many malignancies, serum tumor markers play an important role in patient management. MUC-1 glycoprotein based serum markers (CA15-3 and CA 27.29) are assays approved by the US Food and Drug Administration for monitoring patients with advanced breast cancer. Potential applications include early detection of recurrent disease and monitoring treatment efficacy in patients with advanced disease. While retrospective data regarding the role of CA27.29 correlates well with progression and treatment of metastatic breast cancer, a multicenter prospective study to further assess the role of CA 27.29 for monitoring of locally advanced disease is warranted.",

author = "Vikas Ghai and Kamal Sharma and Abbi, {Kamal K.S.} and Harvey, {Harold A.}",

year = "2011",

doi = "10.2174/1876817201103010029",

language = "English (US)",

volume = "3",

pages = "29--30",

journal = "Open Breast Cancer Journal",

issn = "1876-8172",

publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Clinical utility of monitoring serial CA 27.29 in patients with different stage of breast cancer

AU - Ghai, Vikas

AU - Sharma, Kamal

AU - Abbi, Kamal K.S.

AU - Harvey, Harold A.

PY - 2011

Y1 - 2011

N2 - Breast cancer is by far the most frequent cancer in women, worldwide and ranks third overall when both sexes are considered together. For many malignancies, serum tumor markers play an important role in patient management. MUC-1 glycoprotein based serum markers (CA15-3 and CA 27.29) are assays approved by the US Food and Drug Administration for monitoring patients with advanced breast cancer. Potential applications include early detection of recurrent disease and monitoring treatment efficacy in patients with advanced disease. While retrospective data regarding the role of CA27.29 correlates well with progression and treatment of metastatic breast cancer, a multicenter prospective study to further assess the role of CA 27.29 for monitoring of locally advanced disease is warranted.

AB - Breast cancer is by far the most frequent cancer in women, worldwide and ranks third overall when both sexes are considered together. For many malignancies, serum tumor markers play an important role in patient management. MUC-1 glycoprotein based serum markers (CA15-3 and CA 27.29) are assays approved by the US Food and Drug Administration for monitoring patients with advanced breast cancer. Potential applications include early detection of recurrent disease and monitoring treatment efficacy in patients with advanced disease. While retrospective data regarding the role of CA27.29 correlates well with progression and treatment of metastatic breast cancer, a multicenter prospective study to further assess the role of CA 27.29 for monitoring of locally advanced disease is warranted.

UR - http://www.scopus.com/inward/record.url?scp=80055109955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055109955&partnerID=8YFLogxK

U2 - 10.2174/1876817201103010029

DO - 10.2174/1876817201103010029

M3 - Article

AN - SCOPUS:80055109955

SN - 1876-8172

VL - 3

SP - 29

EP - 30

JO - Open Breast Cancer Journal

JF - Open Breast Cancer Journal

ER -

Clinical utility of monitoring serial CA 27.29 in patients with different stage of breast cancer

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this